Globally, the rapid advancement of artificial intelligence (AI) and machine learning (ML) raises fundamental questions about how the technology can be used. Drug approval authorities are now also taking part in this discussion, resulting in emerging and evolving guidelines and principles for drug companies.
The post EU, U.S., and UK Regulatory Developments on the Use of Artificial Intelligence in the Drug Lifecycle appeared first on Data Matters Privacy Blog.